Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
Liraglutide is an FDA-approved GLP-1 receptor agonist with 15+ years of market data and proven cardiovascular protection from the LEADER trial (n=9,340). Less potent than semaglutide for weight loss, but side effects clear in a day thanks to its 13-hour half-life.
600mcg · Daily
Summary: Add 0mL BAC water to your 18mg vial. Draw to < 0.1 units on a U-100 syringe for a 600mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 600mcg | Daily |
| Moderate | 1,800mcg | Daily |
| Aggressive | 3mg | Daily |
Liraglutide comes as a pre-filled pen, so there's no reconstitution math to worry about. Saxenda pens hold 18 mg total and deliver doses from 0.6 mg to 3.0 mg via a dial selector. At the 3 mg maintenance dose, one pen lasts 6 days. For compounded liraglutide from 503A pharmacies, the common concentration is 6 mg/mL. With that concentration in a standard insulin syringe: 10 units equals 0.6 mg, 20 units equals 1.2 mg, 30 units equals 1.8 mg, 40 units equals 2.4 mg, and 50 units equals 3.0 mg. The thing most beginners miss: if you skip more than 3 consecutive days, you need to restart at 0.6 mg and re-titrate. Jumping back to your prior dose after a gap causes disproportionate GI distress. Keep your pens on schedule or plan for the ramp back up. Store unused pens in the fridge (2 to 8 degrees Celsius). Once you start using a pen, it can stay at room temperature (up to 30 degrees Celsius) for 30 days.
Dosing based on Victoza FDA Prescribing Information (2023) — 9 published references.View all sources →
Cross-check your Liraglutide reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Liraglutide is an FDA-approved GLP-1 receptor agonist with 15+ years of market data and proven cardiovascular protection from the LEADER trial (n=9,340). Less potent than semaglutide for weight loss, but side effects clear in a day thanks to its 13-hour half-life.